Navigation Links
Risk Of Birth Defects Increased Due To Anti-Depressant Medication

A warning has been issued to all physicians, more specifically to pregnant women against the prescription and consumption of Paxil, given for treatment of depression due to the risk of increased congenital// heart defects in newborns.

The notice has been issued by the Food and Drug Administration (FDA) and is based on early findings of two studies, which had demonstrated that women who took Paxil during the first trimester had a two fold increased risk of giving rise to babies with congenital heart defects compared to other pregnant women. The risk of birth defect was significantly higher compared to pregnant women who took other forms of anti-depressant medication.

In the studies cited by the FDA, the risk of congenital heart defects is about 1 percent overall, which rose to 1.5 to 2 percent in infants born to women taking Paxil. Following the notification, the drug has been placed in the second highest category for risk of birth defects. It is generally advisable to avoid all drugs during pregnancy. However in case use of an anti-depressant medication is very necessary, it is safer to use other medicines as a substitute after a careful consultation with the physician.

The physicians have also been alerted regarding the adverse effects arising out of sudden withdrawal of Paxil. Though it was known that selective serotonin reuptake inhibitors (SSRIs) could harm fetuses, the magnitude of the risk has not been studied previously. The recent report by the FDA and GlaxoSmithKline (manufacturer of Paxil) is the only strong evidence that it can result in birth defects.

Approximately 20% of all pregnant women are estimated to suffer from some form of depression. This creates confusion about the initiation and continuation of anti-depressant medication in pregnancy. The increased tendency of pregnant women to display irritable behaviour, tremors and seizures following childbirth has posed additional concerns regarding mother’s healt h.

Ever since the time of approval in 1993, the drug has been taken by over millions worldwide. Women of childbearing age (18-45 yrs) constitute 25% of the total number of Paxil users. Although several studies have demonstrated the effectiveness of Paxil in the treatment of depression, anxiety disorder and other psychiatric disorders in adults, the data available on the safe use of Paxil is very limited.

Keeping in mind the above figure, it is high time that certain guidelines are formulated regarding usage of Paxil. Ultimately, the gold standard rule of benefit Vs risk should dictate the indication for use under all circumstances including pregnancy.
'"/>




Related medicine news :

1. Birth weight key factor in heart diseases
2. FDA Approves Birth Control Skin Patch
3. IVF technique May Increase The Risk Of Birth Defects
4. Smoking Linked To Low Infant Birth Weight
5. Unpredictable Premature Birth
6. New Birth Control Pills increase the stroke risk
7. Epilepsy Drugs Can Enhance Risk of Birth Defects
8. Sex timing has no impact on risk of Birth defects
9. Birth weight may be influenced by genes
10. Dental Procedure Reduces Preterm Births
11. Low Birth Weight infants could have Problems in the Future
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology: